卖什么
AI Operating System for Clinical Development
商业模式拆解
买家：谁掌握预算？
未核实Heads of biometrics / clinical development at sponsors, with IT, security and quality teams involved.
触发点：什么让他们现在购买？
Biometrics capacity limits and trial bottlenecks; claims 30-50% faster progress, >1500 potential trial errors avoided, >$10M potential savings identified.
工作流：什么输入变成什么输出？
Map one study data, analysis needs and deliverables, automate repetitive biometrics (SDTM, ADaM, TLFs) in connected workflow with human review gates and traceability from SAP to output.
经济账：省了什么，怎么收费？
未核实Not stated; offers AI-augmented FSP / end-to-end biometrics services plus platform.
渠道：怎么接触到客户？
Demo-led (Request a demo / Book a demo); enterprise deploys inside client environment; conference sponsorship.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2026 春季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.